Linezolid resistance in a clinical isolate of Staphylococcus aureus.
Lancet
; 358(9277): 207-8, 2001 Jul 21.
Article
em En
| MEDLINE
| ID: mdl-11476839
ABSTRACT
The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clinical isolates of S aureus. We have characterised an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-associated peritonitis.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções Estafilocócicas
/
Staphylococcus aureus
/
Inibidores da Síntese de Proteínas
/
Oxazolidinonas
/
Acetamidas
/
Antibacterianos
Limite:
Aged
/
Aged80
/
Humans
/
Male
Idioma:
En
Revista:
Lancet
Ano de publicação:
2001
Tipo de documento:
Article